Reported 2 days ago
Raymond James has resumed coverage of Disc Medicine, Inc. (NASDAQ:IRON) with a strong Buy rating and a price target of $89. The firm highlighted the favorable risk/reward profile of Disc Medicine, particularly its potential to generate over $1 billion from its drug bitopertin, which treats X-linked protoporphyria. Disc Medicine is focused on therapies for serious blood diseases, with a diverse pipeline including treatments for conditions like Diamond-Blackfan Anemia and polycythemia vera.
Source: YAHOO